Emerging therapies: Potential roles of SGLT2 inhibitors in the management of pulmonary hypertension
- 15 April 2024
- journal article
- research article
- Published by Elsevier in Respiratory Medicine
- Vol. 227, 107631
Abstract
No abstract availableKeywords
This publication has 77 references indexed in Scilit:
- Dapagliflozin Reduces Pulmonary Vascular Damage and Susceptibility to Atrial Fibrillation in Right Heart DiseaseESC Heart Failure, 2022
- Use of SGLT2 inhibitors and occurrence of noninfectious respiratory disorders: a meta-analysis of large randomized trials of SGLT2 inhibitorsEndocrine, 2021
- Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Endothelial Function: A Systematic Review of Preclinical StudiesDiabetes Therapy, 2020
- Obesity and Pulmonary HypertensionCurrent Hypertension Reports, 2018
- SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art reviewDiabetologia, 2018
- Empagliflozin Reduces Ca/Calmodulin-Dependent Kinase II Activity in Isolated Ventricular CardiomyocytesESC Heart Failure, 2018
- Pulmonary vascular remodeling in pulmonary hypertensionCell and tissue research, 2016
- Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbitsDiabetologia, 2016
- Calcium homeostasis modulator (CALHM) ion channelsPflügers Archiv - European Journal of Physiology, 2015
- Acute effects of glucose and insulin on vascular endotheliumDiabetologia, 2004